Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody "LEQEMBI®" has been ...

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

Ronald McDonald House Charities of South Louisiana(RMHCSLA) is pleased to welcome Ryan Furby and Duncan Brown to its Board of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

SOS Ltd., a multifaceted company that engages in the blockchain, cryptocurrency operations and commodity trading, today announced the Board of Directors approved its plan to invest $50 million to ...

Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

"Samsung Biologics inks $668m manufacturing deal with European pharma " was originally created and published by ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

After getting a green light from the European Commission, Biogen ... In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius ...

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...